Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

BACKGROUND:  First-line treatment of nonsquamous non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with immune checkpoint inhibitors (ICIs). However, phase III studies of combinations of cytotoxic chemotherapy and ICIs have included only patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiraishi, Yoshimasa, Kishimoto, Junji, Shimose, Takayuki, Toi, Yukihiro, Sugawara, Shunichi, Okamoto, Isamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461146/
https://www.ncbi.nlm.nih.gov/pubmed/36076179
http://dx.doi.org/10.1186/s12885-022-10056-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461146/
https://www.ncbi.nlm.nih.gov/pubmed/36076179
http://dx.doi.org/10.1186/s12885-022-10056-x

Ejemplares similares